Global Bipolar
Disorder Treatment Market, By Drug Class (Antipsychotics, Antidepressants,
Mood Stabilizers, and Anti-anxiety Drugs and Others), By Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
is estimated to be valued at US$ 7,288.3 million in 2019 and is expected to
exhibit a CAGR of 5.2% over the forecast period (2019-2027), as highlighted in
a new report published by Coherent Market Insights.
Governments and healthcare
organizations are supporting various clinical developmental stage companies and
research organizations to develop novel drugs for the treatment of bipolar
disorder, which is likely to drive the market growth over the forecast period.
For instance, in January 2018, European Union’s Horizon 2020 Research and
Innovation program awarded grant of US$ 8.8 million to R-Link, a cohort study
for lithium initiation. The R-Link study has been initiated by researchers at
Centre for Affective Disorders, Department of Psychological Medicine at the
Institute of Psychiatry, Psychology & Neuroscience, King’s College London.
Moreover, in June 2017, the Iowa
Neuroscience Institute announced that it will grant fund of US$ 150,000
annually for five years to psychiatry research center (Department of Psychiatry
in University of Iowa), in order to create a Bipolar Disorder Research Program
of Excellence.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2605
Browse 27 Market Data Tables and
26 Figures spread through 201 Pages and in-depth TOC on “Bipolar Disorder
Treatment Market”- Global Forecast to 2027, by Drug Class (Antipsychotics,
Antidepressants, Mood Stabilizers, and Anti-anxiety Drugs and Others), by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa).
Major players operating in the
bipolar disorder treatment market are collaborating and partnering to focus on
various operations ranging from research and development, manufacturing, sales
and distribution, and others of bipolar disorder drugs, which is expected to
boost the market growth over the forecast period. For instance, in February
2016, Sound Pharmaceuticals (SPI) announced collaboration with University of
Oxford, in order to develop novel treatment for bipolar disorder. Under this
collaboration agreement, in November 2017, both the companies collaboratively
initiated the Phase II clinical trial for SPI-1005 for the treatment of
patients with bipolar disorder. SPI-1005 is an oral drug containing ebselen,
which mimics and induces the activity of Glutathione Peroxidase (GPx) in the
inner ear and brain. The study was completed in July 2019.
Key Takeaways of the Global Bipolar
Disorder Treatment Market:
The global bipolar disorder
treatment market is expected to exhibit a CAGR of 5.2% over the forecast
period, owing to increasing product launches and approvals, and high prevalence
of bipolar disorder. According to South African Depression & Anxiety Group
published in 2017, the life time prevalence of depression in South Africa is
estimated to be 9.7%, which accounted for 4.5 million patients. Moreover,
according to the same source, bipolar disorder affects 1% of population in
South Africa.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/bipolar-disorders-treatment-market-2605
Among drug class, antipsychotics
segment held the largest market share in 2018, owing to increased prevalence of
bipolar disorder. According to the National Alliance on Mental Illness
Factsheet, September 2019, the annual prevalence of bipolar disorder in the
U.S. was estimated at around 7 million.
Among distribution channel,
retail pharmacies segment held the largest market share in 2018, owing to
patients’ preference to buy products through retail pharmacies and increasing
number of retail or independent pharmacies. According to PLOS Journal, August
2017 findings, the number of independent pharmacies in the U.S. exhibited 3.8%
growth from 22,737 (2007) to 23,596 (2015).
Companies operating in the global
bipolar disorder treatment market include Takeda Pharmaceutical Company
Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson &
Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis
International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo
Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc.,
and Indivior PLC.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2605
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment